Dynamics of lipid metabolism in the combined therapy of antihypertensive and hypolipidemic drugs in patients with metabolic syndrome

Introduction Metabolic syndrome in combination with arterial hypertension is one of the most severe combinations, accompanied by a high risk of progression of cardiovascular complications. The tactics of antihypertensive therapy in metabolic syndrome (MS) is aimed not only at lowering blood pressure, but also primarily at preventing fatal cardiovascular complications.

The aim of the research Evaluation of the effectiveness of combined antihypertensive therapy in combination with a hypolipidemic drug in patients with hypertension with abdominal type of obesity, dyslipidemia and impaired glucose tolerance or fasting hyperglycemia (MS according to IDF criteria, 2005).

Materials and methods of the research The study included 43 patients (20 men and 23 women 43.4±8.1 years). Patients underwent SMAD before the appointment of antihypertensive therapy with Valsortan. According to the classification of the level of hypertension during the SMAD, patients were divided into groups according to the severity of hypertension. Revealed 1 degree – 28 patients (of them men – 12, women - 16), 2 degrees – 15 patients ( 9/7). The background of antihypertensive therapy, repeated SMAD was performed and a decrease in blood pressure to the target value was noted in all patients, an improvement in lipid metabolism was observed in group II (a decrease in total cholesterol from 6.25±0.3 to 5.34± 0.1 mmol/l; low-density lipoproteins from 3.49±0.3 to 2.42±0.1 mmol/l; triglyceride from 1.97±0.2 to 1.58±0.1 mmol/l, a decrease in blood glucose levels was observed in both groups. Conclusion: The use of Valsortan with Atorvastatin causes the hypotensive and hypolipidemic a effect.

Publikationsverlauf

Artikel online veröffentlicht:
02. Mai 2023